Evidence map›Paper›PMID 34637921›Full record

ArticleMolecular metabolism2021

An anaplerotic approach to correct the mitochondrial dysfunction in ataxia-telangiectasia (A-T).

A J Yeo, G N Subramanian, K L Chong, M Gatei, R G Parton, D Coman, M F Lavin

Open access · goldAbstract read
In one paragraph

Article in Molecular metabolism, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

A J YeoUniversity of Queensland Centre for Clinical Research, University of Queensland, Herston, Brisbane, Australia. Electronic address: abrey.yeo@uq.edu.au.
G N SubramanianUniversity of Queensland Centre for Clinical Research, University of Queensland, Herston, Brisbane, Australia.
K L ChongUniversity of Queensland Centre for Clinical Research, University of Queensland, Herston, Brisbane, Australia.
M GateiUniversity of Queensland Centre for Clinical Research, University of Queensland, Herston, Brisbane, Australia.
R G PartonInstitute for Molecular Bioscience and Centre for Microscopy and Microanalysis, University of Queensland, St Lucia, Brisbane, Australia.
D ComanQueensland Children's Hospital, Brisbane, Australia; Faculty of Medicine, University of Queensland, Herston, Brisbane, Australia.
M F LavinUniversity of Queensland Centre for Clinical Research, University of Queensland, Herston, Brisbane, Australia. Electronic address: m.lavin@uq.edu.au.
University of Queensland · AUQueensland Children’s Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundATM, the protein defective in the human genetic disorder, ataxia-telangiectasia (A-T) plays a central role in response to DNA double-strand breaks (DSBs) and in protecting the cell against oxidative stress. We showed that A-T cells are hypersensitive to metabolic stress which can be accounted for by a failure to exhibit efficient endoplasmic reticulum (ER)-mitochondrial signalling and Ca2

methodsWe treated control cells and A-T cells with the anaplerotic agent, heptanoate to determine their sensitivity to metabolic stress induced by inhibition of glycolysis with 2- deoxyglucose (2DG) using live-cell imaging to monitor cell survival for 72 h using the Incucyte system. We examined ER-mitochondrial signalling in A-T cells exposed to metabolic stress using a suite of techniques including immunofluorescence staining of Grp75, ER-mitochondrial Ca

resultsWe demonstrate that heptanoate corrects all aspects of the defective ER-mitochondrial signalling observed in A-T cells. Heptanoate enhances ER-mitochondrial contacts; increases the flow of calcium from the ER to the mitochondrion; restores normal mitochondrial function and mitophagy and increases the resistance of ATM-deficient cells and cells from A-T patients to metabolic stress-induced killing. The defect in mitochondrial function in ATM-deficient cells was accompanied by more reliance on aerobic glycolysis as shown by increased lactate dehydrogenase A (LDHA), accumulation of lactate, and reduced levels of both acetyl CoA and ATP which are all restored by heptanoate.

conclusionsWe conclude that heptanoate corrects metabolic stress in A-T cells by restoring ER-mitochondria signalling and mitochondrial function and suggest that the parent compound, triheptanoin, has immense potential as a novel therapeutic agent for patients with A-T.

Indexed as

Ataxia TelangiectasiaCells, CulturedEndoplasmic ReticulumHumansMitochondriaAtaxia-telangiectasiaATMEndoplasmic reticulum–mitochondrial interactionHeptanoate (C7)Mitochondrial dysfunctionNutrient deprivation

Identifiers

PMID34637921
PMCPMC8599162
OpenAlexW3206113032

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.